CG
ATYR

Cutler Group’s aTyr Pharma ATYR Stock Holding History

Cutler Group’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-21,500
Closed -$45K – 6252
2021
Q3 		$45K Buy
+21,500
New +$129K ﹤0.01% 2607

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cutler Group's ATYR Position: Q2 2022 in Review

Cutler Group sold out of aTyr Pharma (ATYR) in Q2 2022, closing a stake of 85 shares.

Cutler Group first reported a position in ATYR in Q3 2021 and held it in 3 quarters. The position peaked at $140K in Q3 2021. 36 funds tracked by Wall St. Rank hold ATYR as of Q2 2022.

  • Cutler Group reported no remaining aTyr Pharma position as of Q2 2022 after selling out during the quarter.
  • Cutler Group sold 85 aTyr Pharma shares in Q2 2022.
  • Cutler Group first reported a position in aTyr Pharma in Q3 2021 and held it in 3 quarters.
  • Cutler Group's aTyr Pharma position peaked at $140K in Q3 2021.
  • 36 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.